A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Antiretroviral therapy (medicines used to treat HIV) can interact with hormonal
contraceptives which might decrease their effectiveness. The single-rod etonogestrel
contraceptive implant is being more commonly used in low- and middle-income countries because
if the ease of insertion and removal. Efavirenz and nevirapine are first-line HIV medicines
in Sub-Saharan Africa and this study will help determine an effective way to use these
medicines with the etonogestrel implant. The investigators hypothesize that women receiving
nevirapine- or efavirenz-based antiretroviral therapy will have lower etonogestrel levels in
their blood after six months of insertion as compared to women not taking antiretroviral
therapy.